Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

de Mendoza C, Ramos JT, Ciria L, Fortuny C, García FJ, de José MI, Asensi F, Soriano V.

HIV Clin Trials. 2002 Jan-Feb;3(1):9-16.

PMID:
11819180
2.
3.

Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.

Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C.

AIDS. 1999 Jul 30;13(11):F87-93.

PMID:
10449279
4.

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.

French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators..

HIV Clin Trials. 2002 May-Jun;3(3):177-85. Erratum in: HIV Clin Trials 2002 Nov-Dec;3(6):following table of contents.

PMID:
12032876
5.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
6.

Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.

Raffi F, Reliquet V, Auger S, Besnier JM, Chennebault JM, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S.

AIDS. 1998 Oct 22;12(15):1999-2005.

PMID:
9814868
7.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
8.

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.

Elion R, Kaul S, Knupp C, Adler M, Cross AP, Dunkle LM, Kelleher T.

Clin Ther. 1999 Nov;21(11):1853-63.

PMID:
10890257
9.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group..

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
10.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
11.

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.

Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM.

JAMA. 1998 Mar 25;279(12):930-7.

PMID:
9544767
12.

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.

García F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miró JM, Gatell JM; Spanish SCAN Study Group..

AIDS. 2000 Nov 10;14(16):2485-94.

PMID:
11101059
13.

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.

Antivir Ther. 2002 Dec;7(4):283-7.

PMID:
12553483
14.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team..

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
15.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

16.

Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.

Int J STD AIDS. 2003 May;14(5):350-5.

PMID:
12803944
17.

Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.

Raffi F, Reliquet V, Francois C, Garre M, Hascoet C, Allavena C, Arvieux C, Breux JP, Perre P, Rozenbaum W, Auger S.

Antivir Ther. 1998;3 Suppl 4:57-60.

PMID:
10723512
18.

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F; FTC-301A Study Team..

JAMA. 2004 Jul 14;292(2):180-9.

PMID:
15249567
19.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
20.

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J.

Antivir Ther. 2003 Apr;8(2):173-82.

PMID:
12741630

Supplemental Content

Support Center